Top Research Papers on Ulcerative Colitis

Skin and soft tissue infections (SSTIs) are among the most common sites of bacterial infection and a cause of considerable morbidity and risk factors include the presence of neoplasia in the original operative specimen,Type C changes and diagnosis of UC of more than 10 years.

The hyperemia component of the EUS-UC score performed significantly better than the original index from which it was derived, but the reliability of the DOI component was suboptimal.

In Pediatric patients with newly diagnosed UC, TABUS was a useful tool, with the UC-IUS and BWT correlating well with their endoscopic, clinical, and biochemical disease activity.

This is the first ever study to investigate whether animal-based protein supplements influence the ability of adults with quiescent UC to maintain remission, and to explore the mechanistic basis and relationship between dietary substrate, gut microbiota, and disease activity.

A unique case of a 70-year-old presenting ulcerative colitis with immune thrombocytopenic purpura is presented, presenting a unique case of a 70-year-old presenting ulcerative colitis with immune thrombocytopenic purpura.

A chronology of key events leading to and following the formation of the Asociaţia Persoanelor cu Boli Inflamatorii Intestinale din România, which led to the establishment of the Romanian Association of People with IBD.

During follow-up of patients in the PPT, Laiyemo et al found that, although many low-risk patients have been verutilizing surveillance colonoscopy, underutilization as common among high- risk patients (Gastroenterolgy 2008;134:A111).

Bowel wall thickness (BWT) and UC-IUS Index performed in children at diagnosis in comparison to endoscopy using the Mayo score and correlated highly positively with the Mayo subscore in children with UC.

The TUMMY-UC, constructed from PRO and ObsRO versions, is a reliable, valid and responsive index, which can be now used in practice and clinical trials.

A new simplified endoscopic index for ulcerative colitis is proposed, the SES-UC, which is based on the two descriptors vascular pattern and ulcers, which displayed similar levels of reliability and accuracy as the established indices.

A high prevalence of infection with at least one or six non-pathogenic and pathogenic intestinal protozoa in UC patients in the Isfahan region is revealed.

The case of a patient with ulcerative colitis who achieved remission with infliximab, however, after about two years of infusions, developed evidence of non-specific interstitial pneumonitis (NSIP); clinical, laboratory, and radiographic findings were sufficient in establishing this diagnosis.

It is shown that appendicectomy has a strong negative association with UC and a more benign UC phenotype and PSC, and removal of an appendix in patients who are susceptible to UC may predispose to a more innocuous UC phenotype.

An UC-IUS index was developed which showed strong correlation with endoscopic disease activity using internal validation and is currently being validated in prospective studies.

Patients receiving etrasimod demonstrated no increased risk of infection and the incidence of serious infections and herpes zoster was similar in each group, and no association between ALC and ALC and infection events was observed.

Comparing patients with CD with active and inactive disease showed a trend of increased levels of thromboxane B2, leukotriene B4 and 9S-HODE in the active versus the inactive disease, indicating the activity of the 15-LOX pathway in CD.

Anti-OMPC may be a useful marker not only for diagnosis of UC but also in determination of the disease activity among UC patients.

Data support conceptual equivalence between the PRO and obsRO TUMMY-UC versions, and provide support for their incorporation into one score.

One-third of patients with UC treated with tofacitinib achieved clinical remission with few serious adverse events, however, half of patients lost response with de-escalation, which was only partially recaptured with increasing the maintenance dose.

In this study, a novel MC/HA-Me enema smart hydrogel was developed for treating UC and the control of adhesion time to the intestinal wall was achieved by adjusting the ratio of MC and HA-Me compounds.

According to many studies issued in the literature, a greater fraction of thyroid disease in inflammatory bowel disease patients has been noted.

UC is inadequately managed in primary care once remission is induced, with several patients missed routine surveillance colonoscopy and blood tests.

Overall there are strong indicators of metabolic changes in the urine of patients with active UC and control samples and some of the putative markers e.g. glutamine are relatively abundant and may be suitable for a simple urinary test.

A standardization method based on deep learning is introduced to address the issue of inconsistent diagnoses of ulcerative colitis by introducing a consensus model that considered only the images and labels on which more than half of the experts agreed.

A randomized controlled trial of a humanized Alpha 4 Beta 7 antibody in Ulcerative Colitis and its application in UC is described.

The cytokine gene polymorphisms evaluated in this study do not seem to be strong risk factors for the overall disease susceptibility in UC, but may be involved in determining the severity of the disease.

Investigating the human TM (hTM) isoforms recognized by serum IgG from UC and whether hTM IgG antibodies are present in healthy UC relatives concluded that autoimmunity to hTM1 and hTM5 is a feature of UC, while h TM1 IgG differentiate UC relatives from controls.

Qingweilichang Capsule can improve the pathological changes and regulate the immunology functions of rats with UC and reduce inflammatory reactions including the tissue ulceration, cell infiltration and the tissue edema.

This research highlights the need to select patients with a history of Crohn’s Disease or ulcerative colitis to be screened for this condition before they begin treatment with chemotherapy.

There is a high burden of unjustified underfeeding among hospitalized patients with UC, particularly in patients admitted without evidence of objective disease flare, which may lead to nutritional compromise in an at-risk population, and targeted quality improvement interventions are needed.

Two miRNAs and three genes associated with the differential manifestations of UC in Uyghur and Han population were identified, which were potential biomarkers of UC.

The frequency and duration of bowel rest orders and the number of meals missed because of these orders were assessed and predictors of unjustified fasting in admitted UC patients were identified.

The SCCAI is a simple tool that can be accurately self administered, correlates well with a more complicated disease activity index, & can be used to define relapse of UC with high specificity & sensitivity.

Patients with UC receiving vedolizumab had a lower risk of dose escalation and lower subsequent costs than patients receiving anti–TNF-α treatments, and index drug costs after dose escalation were lowest for vedlizumabs.

This review emphasizes the virological tools that are recommended for exploring CMV colitis during inflammatory bowel diseases (IBD) and underlines the interest of using ganciclovir for treating flare-ups associated to CMVcolitis in UC patients.

VDZ serum concentrations were positively associated with Histological remission in UC, although the predictive value of serum concentrations for subsequent histological remission was modest.

Patients receiving intensified or accelerated induction achieved clinical and biochemical remission earlier compared to standard induction; however, outcomes at three months were similar and patients with a lower albumin may benefit from proactive intensified dosing strategies.

The UC Horizons Project raised a series of eminently practical questions about the management of UC and provided responses based on the best scientific evidence available, although the quality of the evidence was markedly heterogeneous.

A study of HLA class II gene association with UC in a large group of white Madrid patients and ethnically matched controls, using molecular biology techniques to investigate whether any allelic subspecificity within the HLA‐DR2 group is associated with susceptibility to or protection against UC.

HIF-1α as a transcriptional factors may be involved in the pathogenesis and activity of UC.

UC HAT did not improve disease activity, QoL, or adherence compared to BAC after 1 year, and research is indicated to determine if telemedicine improves outcomes in patients with IBD.

In the experience FT might be safe but activates a temporary systemic immune response and the general well-being improved from poor to very well at week 12 in the other 3 patients, but the median total Mayo score improved only from 11 to 9.

This JAMA Patient Page describes the condition of ulcerative colitis and its symptoms, diagnosis, and treatment options.

The future will likely see an array of new therapeutic options for those with ulcerative colitis with the potential for a more personalised treatment approach.

A model developed, based on simplified decision tree pathways, can be used for economic evaluations of interventions to reduce the risk of flare in UC and to help understand the costly aspects of managing ulcerative colitis.

A UC Diet alone appeared to achieve higher clinical remission and mucosal healing than single donor FT with or without diet in mild to moderate UC failing medical therapy and this diet should be investigated further in a RCT specifically designed for the UCD.

The percentage phyla and the abundance of putative pathogenic bacteria could be used to predict the evolution tendency of ulcerative colitis patients and the bacterial composition of severe UC was distinctly different from others.

The fully-automated UC-SCALE algorithm provides a topological representation of the score as a marker of disease severity that correlates highly with clinical metrics and holds promise to enhance disease severity evaluation in both clinical trials and everyday practice.

An effective treatment for mild to moderate UC is 5-aminosalicylic acid, whereas moderate to severe UC can be treated with advanced therapies that target specific inflammation pathways, including monoclonal antibodies to tumor necrosis factor, α4β7 integrins, and IL-12 andIL-23 cytokines, as well as oral small molecule therapies targeting janus kinase or sphingosine-1-phosphate.

This research highlights the need to select patients with a history of Crohn’s Disease or ulcerative colitis to be screened for this condition before they begin treatment with chemotherapy.